-
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Months to 17 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety
NCT07019922 ·
Phase: Phase 3 ·
Ages: 1 Day to 18 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125 ·
Phase: Phase 3 ·
Ages: 2 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
NCT07227857 ·
Phase: Phase 1, Phase 2 ·
Ages: 2 Years to 12 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
NCT05716100 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770 ·
Phase: Phase 3 ·
Ages: 2 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Cleveland, Columbus
-
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
NCT06132893 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Canton, Cincinnati, Columbus
-
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures
NCT05667142 ·
Phase: Phase 3 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· Ohio: Akron, Cleveland, Columbus
-
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
NCT06063850 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cleveland, Columbus
-
An Examination of Whether Infrared Light Therapy Can Reduce Stress in People With Epilepsy
NCT07509177 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cincinnati, Warren
-
Biology of Juvenile Myoclonic Epilepsy
NCT03400371 ·
Phase: Not specified ·
Ages: 10 Years to 40 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Bridging the Gap: Educating Patients on Social Determinants of Health to Improve Epilepsy Surgery Access and Outcomes
NCT07509190 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· Ohio: Cleveland
-
Comparative Effectiveness of Palliative Surgery Versus Additional Anti-Seizure Medications for Lennox-Gastaut Syndrome
NCT05374824 ·
Phase: Not specified ·
Ages: Up to 26 Years ·
Sex: All (male and female)
· Ohio: Columbus
-
Diagnosing Epilepsy To EffeCT Change
NCT07110337 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Clevland
-
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454 ·
Phase: Not specified ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
ESIS in Pediatric DRE
NCT05469373 ·
Phase: Not specified ·
Ages: 1 Year to 30 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy
NCT06608966 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 13 Years to 17 Years ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Epilepsy Learning Healthcare System (ELHS)
NCT06265103 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Ohio: Akron, Cincinnati
-
Healthy Aging in People With Epilepsy Program
NCT06052605 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 55 Years to 90 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)
NCT01694940 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Ohio: Akron, Cleveland, Clevland
-
Prospective Natural History Study of POLG Disease
NCT07775872 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· Ohio: Akron
-
Readiness Brain Operation Optimization Training (ReBOOT) for Epilepsy Surgery
NCT05992402 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female)
· Ohio: Cleveland
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
NCT05104983 ·
Phase: Phase 2 ·
Ages: 1 Day to 6 Months ·
Sex: All (male and female)
· Ohio: Cincinnati
-
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· Ohio: Cleveland